Eli Lilly and Co.
(NYSE:LLY) stock traded higher Wednesday after the drugmaker reported second-quarter results that topped Wall Street expectations and raised its full-year revenue outlook, driven by continued demand for its diabetes and obesity treatments.
The company's obesity and diabetes franchise remained its biggest growth engine in the second quarter, with blockbuster GLP-1 drugs Mounjaro and Zepbound generating a combined $14.9 billion in revenue.
The two products added $6.3 billion in year-over-year sales, underscoring strong demand for Eli Lilly's weight-loss and diabetes treatments as the company continues to expand access, launch new products and strengthen its leadership in the fast-growing GLP-1 market.
Mounjaro And Zepbound Drive Strong Quarter Adjusted earnings rose to $8.38 per share, beating the analyst consensus estimate of $6.01.
